INDOCO logo

Indoco Remedies Limited Stock Price

NSEI:INDOCO Community·₹18.4b Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 19 Fair Values set on narratives written by author

INDOCO Share Price Performance

₹0
-241.99 (-100.00%)
₹380.00
Fair Value
₹0
-241.99 (-100.00%)
Price ₹0

INDOCO Community Narratives

·
Fair Value ₹380 48.5% undervalued intrinsic discount

Indoco Remedies Will Benefit from India's Healthcare Growth

0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
·
Fair Value ₹250 21.7% undervalued intrinsic discount

US And EU Regulation Will Hamper Long-Term Profitability

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value ₹260 24.7% undervalued intrinsic discount

Regulatory Challenges And Capacity Expansion Will Reshape Future Potential

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
₹380
48.5% undervalued intrinsic discount
Profit Margin
14.76%
Future PE
22.08x
Price in 2030
₹672.4
₹250
21.7% undervalued intrinsic discount
Profit Margin
9.07%
Future PE
10.37x
Price in 2029
₹352.26
₹260
24.7% undervalued intrinsic discount
Profit Margin
10.5%
Future PE
10.32x
Price in 2028
₹377.21

Trending Discussion

Updated Narratives

INDOCO logo

Indoco Remedies Will Benefit from India's Healthcare Growth

Fair Value: ₹380 48.5% undervalued intrinsic discount
10 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
INDOCO logo

INDOCO: Ophthalmic Business Transfer And ANDA Approval Will Shape Balanced Outlook

Fair Value: ₹250 21.7% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
INDOCO logo

Regulatory Challenges And Capacity Expansion Will Reshape Future Potential

Fair Value: ₹260 24.7% undervalued intrinsic discount
6 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with reasonable growth potential.

1 Risk
4 Rewards

Indoco Remedies Limited Key Details

₹18.5b

Revenue

₹5.4b

Cost of Revenue

₹13.0b

Gross Profit

₹14.0b

Other Expenses

-₹951.5m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-10.31
70.64%
-5.16%
111.1%
View Full Analysis

About INDOCO

Founded
1945
Employees
6000
CEO
Sundeep Bambolkar
WebsiteView website
www.indoco.com

Indoco Remedies Limited manufactures and markets formulations and active pharmaceutical ingredients in India and internationally. It offers products for gastrointestinal, anti-infectives, respiratory, stomatological, vitamins/minerals/nutrients, urological, ophthal/ontological, dermatology, pain/analgesic, cardiac, anti-diabetic, and gynaecological therapeutic areas. The company also provides branded generics comprising analgesic tablets and topical preparations; anti-hypertensive; protein supplements; multivitamin tablets and syrups; antibiotic tablets, syrups, and injectables; oral rehydration powders; antacids; and antihistaminic, anti-inflammatory drugs, etc. In addition, it provides analytical services, such as impurity profile, particle size analysis, polymorphism and compatibility studies, heavy metal analysis, extractables and leachables studies, lyophilization studies, reference and working standards, forced degradation studies, and chromatographic method development and validation services. Further, the company offers architectural design, lighting, mechanical and utility engineering, project and construction management, electrical, control system, piping, structural design, data transfer system, and process engineering. Additionally, it provides contract research services, such as custom chemical synthesis of molecules and intermediates; process chemistry research and development; non-infringing process designing and scale up; and analytical method development, validation, impurity characterization, and polymorphic studies, solutions, as well as intellectual property management. The company was formerly known as Indo Continental Trading Company. Indoco Remedies Limited was founded in 1945 and is based in Mumbai, India.

Recent INDOCO News & Updates

Narrative Update May 09

INDOCO: Ophthalmic Business Transfer And ANDA Approval Will Shape Balanced Outlook

Analysts have raised their price target on Indoco Remedies from ₹207 to ₹250, citing revised assumptions for the discount rate, revenue growth, profit margin, and future P/E ratio that together suggest a higher estimated fair value for the stock. What's in the News A board meeting is scheduled for April 30, 2026, to consider transferring Indoco Remedies' ophthalmic business in India and agreed territories in Africa to Sunways (India) Private Limited, on terms set out in a business transfer agreement (Key Developments).

Recent updates

No updates